Circulating Non-Coding RNAs as Liquid Biopsy Biomarkers for Early Detection of Triple-Negative Breast Cancer: From Diagnostic Performance to Clinical Translation
Diagnostics · 30.10.2026 · 16 (21) · 3591
DOI: 10.3390/diagnostics16213591 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 30.10.2026. Verfasst von Ivayla Kuleva und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Faculty of Pharmacy, Medical University of Varna, 84 Tzar Osvoboditel Blvd., 9002 Varna, Bulgaria. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Triple-negative breast cancer (TNBC) is an aggressive and molecularly heterogeneous breast cancer subtype for which early detection remains clinically important. Circulating non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are being investigated as blood-based biomarkers. This narrative review evaluates the clinical evidence for circulating ncRNAs as liquid-biopsy biomarkers for early TNBC detection, focusing on stage I–II disease, diagnostic performance, comparator selection, and validation.
Methods
Peer-reviewed studies published between 2009 and October 2026 were identified primarily through PubMed/MEDLINE searches, supplemented by Google Scholar searches, with particular attention to disease stage, comparator populations, diagnostic performance, and validation status.
Results
Among the ncRNA classes reviewed, circulating miRNAs provide the most directly relevant, although still limited, clinical evidence for early-stage TNBC detection, whereas evidence for lncRNAs and circRNAs remains predominantly exploratory and insufficiently validated for early-stage detection. Translation is limited by small, heterogeneous cohorts, analytical variability, and insufficient independent and prospective validation.
Conclusions
High diagnostic accuracy in selected cohorts does not establish clinical readiness. Standardized analytical workflows, independent multicenter validation, prospective evaluation in intended-use populations, and integration with imaging and clinical assessment are needed before circulating ncRNA signatures can be considered for clinical use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biology, Faculty of Pharmacy, Medical University of Varna, 84 Tzar Osvoboditel Blvd., 9002 Varna, Bulgaria.
ORCID-Profile: Ivayla Kuleva, Stoyan Stoyanov, Tsonka Dimitrova
Zitieren
APA
Kuleva, I., Stoyanov, S., Tsvetkova, M., Ivanova, N., Cherneva, D., Dimitrova, T., & Yaneva, G. (2026). Circulating Non-Coding RNAs as Liquid Biopsy Biomarkers for Early Detection of Triple-Negative Breast Cancer: From Diagnostic Performance to Clinical Translation. Diagnostics, 16(21), 3591. https://doi.org/10.3390/diagnostics16213591
Vancouver
Kuleva I, Stoyanov S, Tsvetkova M, Ivanova N, Cherneva D, Dimitrova T, et al. Circulating Non-Coding RNAs as Liquid Biopsy Biomarkers for Early Detection of Triple-Negative Breast Cancer: From Diagnostic Performance to Clinical Translation. Diagnostics. 2026;16(21):3591. doi:10.3390/diagnostics16213591
BibTeX
@article{Kuleva2026,
author = {Kuleva, Ivayla and Stoyanov, Stoyan and Tsvetkova, Maria and Ivanova, Nikoleta and Cherneva, Dzheni and Dimitrova, Tsonka and Yaneva, Galina},
title = {Circulating Non-Coding RNAs as Liquid Biopsy Biomarkers for Early Detection of Triple-Negative Breast Cancer: From Diagnostic Performance to Clinical Translation},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {21},
pages = {3591},
doi = {10.3390/diagnostics16213591}
}
EUVIMED